C4TS SPRING 2015 NEWSLETTER
Issue 6
2
C4TS SPRING 2015 newsletter
WELCOME
Welcome to the Spring 2015 edition of the Barts Centre for Trauma Sciences (C4TS) Newsletter. We describe progress towards a Phase 2 clinical trial testing a drug that could protect organs in severely injured patients. We also discuss some of our research into trauma induced secondary cardiac injury and throw the spotlight on our efforts to improve the clinical database for EDs in England and Wales. We cover C4TS’s first mouthwatering bake -off to support Barts Charity’s new trauma appeal.
Professor Chris Thiemermman; Lead, Organ Failure and Protection theme
Trauma organ protection - Artesunate Thanks to a Wellcome Trust award of £780,000, C4TS are now seeking regulatory approval to conduct an exciting Phase 2a clinical trial of Artesunate for the protection of organs in severely injured patients with traumatic haemorrhage. Background
As discussed in the Autumn 2014 newsletter, multiple organ failure affects 1 in 3 severely injured patients and, if not fatal, results in worse outcomes such as prolonged critical care needs and poor long-term quality of life. Development of organ failure occurs early (within two days of admission) and correlates with an increase in hospital-acquired infections and if it persists, mortality. Currently there are no specific treatments for organ failure. A therapeutic agent that reduces the incidence and severity of multiple organ failure could have a major global impact on trauma patient outcomes and their demands for healthcare utilization.
By Professor Chris Thiemermman, Lead, Organ Failure and Protection Promising discovery of new use for an old drug
Artesunate is a drug that has been in use for many years as the treatment of choice for severe malaria. It has very few adverse effects and can even be used safely by patients with kidney failure or liver dysfunction. Using experimental (rat) models of severe bleeding, we have discovered that the intravenous injection of small doses of Artesunate (1 to 4.8 mg/kg) upon resuscitation reduces organ failure after trauma haemorrhage.
Figure 1: Artesunate molecular structure
The drug appears to be enhancing the protection of organs by reducing the body’s excessive response (i.e. inflammation) to injury and blood loss, and by activating well-known cell-survival pathways. Click here to find out more about other C4TS research projects.
Translating trauma research into trauma practice This trial of Trauma Organ Protection using Artesunate (TOP-ART) will:
Compare safety and benefit of Artesunate administration to standard treatment in severely injured bleeding trauma patients Be a single-centre study at the Royal London Hospital Major Trauma Centre Recruit 105 adult trauma patients o 35 low dose Artesunate, 35 high dose Artesunate, 35 low dose placebo Enrol eligible patients over 24 month period (starting summer 2015) Determine patient outcomes in hospital for up to 28 days and at 1 year post injury